A Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Condition: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Interventions: Drug: GDC-9545; Drug: GDC-9545-matched Placebo; Drug: Letrozole; Drug: Letrozole-matched Placebo; Drug: Palbociclib; Drug: LHRH Agonist Sponsor: Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials